A phase III multicenter trial comparing two different sequences of second/third line therapy (cetuximab/irinotecan followed by FOLFOX versus FOLFOX followed by cetuximab/irinotecan) in metastatic K-RAS wt colorectal cancer (mCC) patients, refractory to FOLFIRI/Bevacizumab)

被引：1
|
作者：
Cascinu, S. [1 ]
Lonardi, S. [2 ]
Rosati, G. [3 ]
Nasti, G. [4 ]
Zaniboni, A. [5 ]
Romiti, A. [6 ]
Aglietta, M. [7 ]
Bilancia, D.
Iaffaioli, V. [4 ]
Zagonel, V. [2 ]
Giordano, M. [8 ]
Corsi, D. [9 ]
Ferrau, F. [10 ]
Labianca, R. [11 ]
Berardi, R. [12 ]
Rulli, E. [13 ]
Floriani, I. [13 ]
机构：
[1] Azienda Osped Reg Torrette, Clin Oncol Med, Ancona, Italy
[2] Ist Oncol Veneto, UO Oncol Med, Padua, Italy
[3] Azienda Osped S Carlo, UO Oncol Med, Potenza, Italy
[4] INT IRCCS Fdn Pascale, UO Oncol Med, Naples, Italy
[5] Fdn Poliambulanza, UO Oncol Med, Brescia, Italy
[6] AOU Policlin St Andrea, UO Oncol Med, Rome, Italy
[7] Ist Candiolo IRCCS, UO Oncol Med, Candiolo, TO, Italy
[8] Osped St Anna, UO Oncol Med, Como, Italy
[9] Osped San Pietro Fatebenefratelli, UO Oncol Med, Rome, Italy
[10] Osped San Vincenzo, UO Oncol Med, Taormina, Italy
[11] Osped Papa Giovanni XXIII, UO Oncol Med, Bergamo, Italy
[12] Azienda Osped Reginale Torrette, Clin Oncol Med, Ancona, Italy
[13] Ist Ric Farmacol Mario Negri, Lab Ric Clin, Milan, Italy
来源：
EUROPEAN JOURNAL OF CANCER | 2015年 / 51卷
关键词：
D O I：
10.1016/S0959-8049(15)30040-X
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2006
引用
收藏
页码：S329 / S329
页数：1
相关论文
共 50 条
  • [41] Impact of primary tumor location (TL) on outcomes of first-line (1L) FOLFOX-4 (F) ± cetuximab (cet) in patients (pts) with RAS wild-type (wt) metastatic colorectal cancer (mCRC) in the phase 3 TAILOR trial
    Qin, Shukui
    Xu, Jian-Ming
    Wang, Liwei
    Cheng, Ying
    Liu, Tian Shu
    Chen, Jiongjie
    Chen, Wen-Feng
    Li, Jin
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [42] TRUSTY: A randomized multicenter phase II/III study of trifluridine/tipiracil and bevacizumab versus irinotecan, fluoropyrimidine, and bevacizumab as second-line treatment in patients with metastatic colorectal cancer progressive during or following first-line oxaliplatin-based chemotherapy.
    Yoshino, Takayuki
    Oki, Eiji
    Nozawa, Hiroaki
    Nakajima, Takako Eguchi
    Taniguchi, Hiroya
    Morita, Satoshi
    Takenaka, Naruhito
    Ozawa, Daisuke
    Shirao, Kuniaki
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [43] Phase III Randomized, Placebo-Controlled Study of Cetuximab Plus Brivanib Alaninate Versus Cetuximab Plus Placebo in Patients With Metastatic, Chemotherapy-Refractory, Wild-Type K-RAS Colorectal Carcinoma: The NCIC Clinical Trials Group and AGITG CO.20 Trial
    Siu, Lillian L.
    Shapiro, Jeremy D.
    Jonker, Derek J.
    Karapetis, Chris S.
    Zalcberg, John R.
    Simes, John
    Couture, Felix
    Moore, Malcolm J.
    Price, Timothy J.
    Siddiqui, Jehan
    Nott, Louise M.
    Charpentier, Danielle
    Liauw, Winston
    Sawyer, Michael B.
    Jefford, Michael
    Magoski, Nadine M.
    Haydon, Andrew
    Walters, Ian
    Ringash, Jolie
    Tu, Dongsheng
    O'Callaghan, Chris J.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (19) : 2477 - 2484
  • [44] FOLFOX4 versus sequential dose-dense FOLFOX7 followed by FOLFIRI in patients with resectable metastatic colorectal cancer (MIROX): a pragmatic approach to chemotherapy timing with perioperative or postoperative chemotherapy from an open-label, randomized phase III trial (vol 26, pg 340, 2015)
    Hebbar, M.
    Chibaudel, B.
    Andre, T.
    Mineur, L.
    Smith, D.
    Louvet, C.
    Dutel, J. L.
    Ychou, M.
    Legoux, J. L.
    Mabro, M.
    Faroux, R.
    Auby, D.
    Brusquant, D.
    Khalil, A.
    Truant, S.
    Hadengue, A.
    Dalban, C.
    Gayet, B.
    Paye, F.
    Pruvot, F. R.
    Bonnetain, F.
    de Gramont, A.
    ANNALS OF ONCOLOGY, 2015, 26 (05) : 1040 - 1040
  • [45] Impact of primary tumor side (TS) on outcomes of once-every-2-weeks (q2w) cetuximab plus first-line (1L) FOLFOX or FOLFIRI in patients with RAS wild-type (wt) metastatic colorectal cancer (mCRC) in the phase 2 APEC trial.
    Price, Timothy Jay
    Shen, Lin
    Ma, Brigette
    Esser, Regina
    Chen, Wen-Feng
    Gibbs, Peter
    Lim, Robert S. C.
    Cheng, Ann-Lii
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [46] Cetuximab weekly (q1w) versus every two weeks (q2w) plus FOLFOX4 as first-line therapy in patients (pts) with KRAS wild-type (wt) metastatic colorectal cancer (mCRC).
    Ciuleanu, T.
    Nikolic, V.
    Shmueli, E.
    Vrbanec, D.
    Plate, S.
    Krmpotic, Z. M.
    Dank, M.
    Purkalne, G.
    Brodowicz, T.
    Zielinski, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [47] Cetuximab weekly (q1w) versus every two weeks (q2w) plus FOLFOX4 as first-line therapy in patients (pts) with KRAS wild-type (wt) metastatic colorectal cancer (mCRC)
    Ciuleanu, T.
    Nikolic, V.
    Shmueli, E.
    Vrbanec, D.
    Plate, S.
    Krmpotic, Z. M.
    Dank, M.
    Purkaine, G.
    Brodowicz, T.
    Zielinski, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [48] CETUXIMAB WEEKLY (Q1W) VERSUS EVERY TWO WEEKS (Q2W) PLUS FOLFOX4 AS FIRST-LINE THERAPY IN PATIENTS (PTS) WITH KRAS WILD-TYPE (WT) METASTATIC COLORECTAL CANCER (MCRC)
    Ciuleanu, Tudor
    Nikolic, Vladimir
    Shacham-Shmueli, Einat
    Vrbanec, Damir
    Plate, Signe
    Mrsic-Krmpotic, Zrinka
    Kahan, Zsuzsanna
    Purkalne, Gunta
    Brodowicz, Thomas
    Zielinski, Christoph
    ANNALS OF ONCOLOGY, 2011, 22 : v22 - v22
  • [49] Final analysis of the phase 2 APEC study: Overall survival (OS) data and biomarker subanalyses for first-line FOLFOX or FOLFIRI with cetuximab (cet) once every 2 weeks in patients (pts) with KRAS or RAS (KRAS and NRAS, exons 2-4) wild-type (wt) metastatic colorectal cancer (mCRC).
    Cheng, Ann-Lii
    Cornelio, Gerardo H.
    Shen, Lin
    Price, Timothy Jay
    Yang, Tsai-Sheng
    Chung, Ilk Joo
    Dai, Guanghai
    Lin, Jen-Kou
    Sharma, Atul
    Yeh, Kun-Huei
    Ma, Brigette
    Zaatar, Adel
    Guan, Zhongzhen
    Masood, Nehal
    Srimuninnimit, Vichien
    Yau, Thomas Cheung
    Beler, Frank
    Chatterjee, Suipto
    Lim, Robert S. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [50] Final analysis of the phase III randomized trial of cetuximab (CET) plus either brivanib alaninate (BRIV) or placebo in patients (pts) with chemotherapy refractory, K-RAS wild-type (WT), metastatic colorectal carcinoma (mCRC): The NCIC Clinical Trials Group and AGITG CO.20 trial
    Siu, Lillian L.
    Shapiro, Jeremy David
    Jonker, Derek J.
    Karapetis, Christos Stelios
    Zalcberg, John Raymond
    Simes, John
    Couture, Felix
    Moore, Malcolm J.
    Price, Timothy Jay
    Siddiqui, Jehan
    Nott, Louise M.
    Charpentier, Danielle
    Liauw, Winston S.
    Sawyer, Michael B.
    Jefford, Michael
    Magoski, Nadine M.
    Haydon, Andrew Mark
    Walters, Ian B.
    Tu, Dongsheng
    O'Callaghan, Christopher J.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345